# Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

> **NCT05316246** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 40 (estimated)

## Conditions studied

- NK/T Cell Lymphoma Nos

## Interventions

- **DRUG:** Brentuximab Vedotin in Combination with Tislelizumab

## Key facts

- **NCT ID:** NCT05316246
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316246, "Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05316246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*